ArticleScientific reports2025
Concentrated growth factors as a graft material for endoscopic revision tympanoplasty.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of concentrated growth factor (CGF) in type 1 tympanoplasty.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Key Techniques and Outcome Analysis of Endoscopic Mastoid Revision Surgery.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aims to evaluate the clinical efficacy of concentrated growth factors (CGF) as a graft material in endoscopic revision tympanoplasty for tympanic membrane perforation. A retrospective analysis was conducted on 30 cases of endoscopic revision tympanoplasty performed at the Otolaryngology Department of Shenzhen Nanshan People's Hospital between January 1, 2019, and December 31, 2023. Fifteen patients were assigned to the experimental group, in which CGF was used for perforation repair, while the control group (n = 15) received cartilage and perichondrium grafts. Surgical outcomes (intraoperative blood loss, operative time), complications (taste disturbance, ear numbness, postoperative pain, ear fullness, incision infection, etc.), postoperative hearing improvement, and follow-up results (tympanic membrane healing time and healing rate) were statistically analyzed between the two groups. Tympanic membrane perforations in both groups achieved complete healing during follow-up. The experimental group exhibited significantly reduced intraoperative blood loss (15.2 ± 3.8 mL vs. 28.6 ± 5.2 mL; P = 0.003), shorter operative time (52.4 ± 10.1 min vs. 78.9 ± 12.6 min, P = 0.001), lower postoperative complication rates (0% vs. 26.7%; P = 0.021), and accelerated tympanic membrane healing time (14.5 ± 2.3 days vs. 21.8 ± 3.7 days; P < 0.001) compared to the control group. However, no significant differences were observed in postoperative hearing outcomes (air-bone gap closure: 12.1 ± 3.5 dB vs. 13.4 ± 4.1 dB; P = 0.32) or tympanic membrane healing rates (93.3% vs. 86.7%, P = 0.48). Concentrated growth factors are effective and safe as a graft material in endoscopic revision tympanoplasty. CGF is readily available, minimally invasive, and particularly advantageous for use in endoscopic revision tympanoplasty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.